Advertisements

Uriprim 300

Quick links to important sections

Uriprim 300

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Uriprim 300

Quick Facts

Property Description
Active Ingredient Allopurinol
Form Oral Tablet
Pharmacological Class Xanthine Oxidase Inhibitor
General Purpose Urate-lowering (Antihyperuricemic)
Origin Synthetic Compound

1. Uriprim 300: Defining the Urate-Lowering Agent

Uriprim 300 is a pharmaceutical product containing the active ingredient Allopurinol, classifying it as a potent Xanthine Oxidase Inhibitor (XOI). This positions it among the primary Antihyperuricemic Agents, medication types clinically recognized for use in managing elevated systemic uric acid levels. The preparation is consistently presented as an Oral Tablet and is a prescription-only medicine, administered via the oral route. The brand Uriprim provides a standardized dosage form of this compound, which acts as an inhibitor of the xanthine oxidase enzyme.

2. Composition, Origin, and Form of Allopurinol

The therapeutic action relies entirely on the synthetic compound Allopurinol, which is chemically structured as a purine structural analogue. This synthetic nature ensures precise chemical activity. The compound is distinguishable from other urate-lowering agents because of its specific enzyme target. The designation Uriprim 300 identifies the formulation as an Oral Tablet containing 300 mg of the active agent. Unlike combination products, this is a single-ingredient product, which simplifies its metabolic profile.

3. The General Purpose of Enzyme Inhibition

The overriding purpose of therapy with this medication is to generate a sustained hypouricemic action, specifically the reduction of serum uric acid concentration. This general benefit addresses the metabolic issue of chronic hyperuricemia. By reducing the overall formation of this metabolic end product through the inhibition of xanthine oxidase, the drug serves the critical function of maintaining balanced urate levels.

Regulatory References

  1. MedlinePlus: Allopurinol
Advertisements

What side effects are possible with Uriprim 300?

Possible Side Effects and Safety Information

The safety profile of Uriprim 300 (Allopurinol) is based on classifications from governmental regulatory bodies, which organize adverse effects by frequency and the body system affected (System-Organ Class or SOC).

Commonly Documented Adverse Reactions

Adverse reactions classified as Common (occurring in 1/100 to 1/10 patients) in regulatory documents generally include skin rash, nausea, and vomiting. These effects are monitored by health authorities and are frequently observed during clinical use.

System-Organ Classification (SOC)

Official labeling groups adverse effects into systems such as Skin and Subcutaneous Tissue Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders (potential liver function changes). Effects on the Blood and Lymphatic System, such as myelosuppression, are also documented, often categorized as less frequent.

Serious Adverse Reactions and Regulatory Warnings

The drug is associated with rare but potentially life-threatening Severe Cutaneous Adverse Reactions (SCAR), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome. These are explicitly highlighted in regulatory warnings and often occur within the first few months of therapy initiation.

Safety Considerations for Specific Populations

Regulatory documents emphasize that patients with renal impairment require specific safety considerations, as the drug is primarily cleared by the kidneys. Additionally, the presence of the *HLA-B58:01 allele** is noted as a strong risk factor for developing SCAR, particularly in individuals of certain Asian ancestries.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Uriprim 300 (Allopurinol)

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Clinical experience regarding massive acute overdose with allopurinol is not reported in official regulatory documents. Therapeutic overdosage may result in nausea and vomiting.
Emergency-response statements No specific antidote for allopurinol is known.
When immediate medical help is required Patients must seek immediate medical attention for any suspected overdose. Management of therapeutic overdosage requires discontinuing the use of the drug.

Overdose Management and Monitoring

Property Official Regulatory Statement
Supportive management notes Allopurinol and its active metabolite, oxipurinol, are known to be dialyzable compounds. Management procedures include assuring adequate hydration to promote drug excretion.
Monitoring requirements The regulatory profile notes that the clinical usefulness of hemodialysis or peritoneal dialysis in the acute management of allopurinol overdose is unknown.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by stating that no specific antidote is known, mandating that patients seek immediate medical attention for any suspected overdose. The lack of reported clinical experience with massive acute overdose means a defined severe symptomology is unavailable. Management procedures focus on supportive care, such as adequate hydration and drug discontinuation, due to the unknown clinical utility of advanced measures like dialysis.

Advertisements

Therapeutic Uses of Uriprim 300

What Uriprim 300 Treats: Main Uses and Benefits

Uriprim 300 (Allopurinol) is generally used to help manage high levels of uric acid that may cause significant health issues. The primary therapeutic focus is the long-term management of the chronic metabolic condition that underlies gout. It is commonly used for conditions involving episodic or fluctuating manifestations, and is considered relevant for conditions involving the long-term management of chronic hyperuricemia, tophaceous gout, and uric acid kidney stones.

This stable control may support the reduction in the frequency and intensity of painful, recurring acute gout manifestations, which are characterized by symptoms related to inflammatory or irritative states. The medication assists with maintaining functional stability by addressing the accumulation of urate crystals and supports patients during periods of heightened discomfort. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as prophylactic support during intensive chemotherapy treatments, where it may assist in reducing the impact of uric acid spikes on renal stability.

“This approach supports the patient by easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Gout
Primary Goal Supports the long-term management of elevated uric acid levels.
Symptom Support May support the reduction in frequency of acute, painful joint flares.
Key Benefit Provides supportive relief in the context of chronic urate deposits (tophi) and helps address kidney stone risk.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Uriprim 300

The eligibility for using Uriprim 300 (Allopurinol) is strictly defined by regulatory documents, determining who may use the medicine and who is formally restricted or excluded.

Contraindications and Non-Eligible Populations

Category Regulatory Status
Hypersensitivity Contraindicated in patients with a known history of severe hypersensitivity to allopurinol.
Genetic Risk Contraindicated in high-risk patients (e.g., Han Chinese, Thai, or Korean descent) with the *HLA-B58:01 genotype**, due to severe reaction risk.
Symptomatic Status Not recommended for the treatment of asymptomatic hyperuricemia (elevated uric acid without clinical symptoms).

Age and Physiological Restrictions

Adults are the standard eligible population. However, eligibility is restricted in several groups:

  • Pediatric Use: Generally not recommended for children under 15 years, except for specific severe conditions like hyperuricemia related to malignancy.
  • Renal/Hepatic Impairment: Use is conditional and requires cautious monitoring in patients with pre-existing impaired kidney or liver function.
  • Pregnancy and Lactation: Use is not usually recommended during pregnancy and should be avoided while breastfeeding, as the drug and its metabolite pass into breast milk.
Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The following interaction information is based strictly on documentation from government health authorities, detailing specific restrictions and requirements for co-administration.

Uriprim 300 (Allopurinol) has documented pharmacokinetic interactions primarily centered on enzyme-mediated metabolism, particularly with purine analogues. Co-administration with Mercaptopurine or Azathioprine inhibits the oxidative metabolism of these agents, resulting in a mandatory, significant increase in exposure. The regulatory labeling strictly advises against initiating or continuing Allopurinol during treatment with Pegloticase and notes that combination with Didanosine is contraindicated due to heightened toxicity risk.

Interaction Type Interacting Substance Regulatory Implication
Metabolic Inhibition Mercaptopurine, Azathioprine Requires mandatory dose reduction of co-administered drug.
Formal Restriction Pegloticase, Didanosine Strictly contraindicated or not initiated.
Absorption/Timing Aluminium Hydroxide Must be separated by at least three hours for administration.

Pharmacodynamic interactions are noted with Uricosuric Agents (such as Probenecid), which can accelerate the renal clearance of Allopurinol’s active metabolite, potentially reducing its inhibitory effect. Additionally, concurrent use with Thiazide Diuretics or ACE Inhibitors is associated with an increased risk of hypersensitivity reactions, especially in individuals with existing impaired renal function.

Advertisements

Mechanism of Action

Targeted Inhibition of Uric Acid Production

Uriprim 300 exerts its core mechanism by acting as an inhibitor against the enzyme Xanthine Oxidase (XO), the primary biological target responsible for the final steps of purine catabolism. By binding to and blocking this enzyme, the compound prevents the metabolic conversion of precursor purine compounds into uric acid. This molecular action primarily takes place in the liver and intestinal mucosa, where XO activity is highest.

Physiological Urate Concentration Modulation

The blockade of Xanthine Oxidase initiates a mechanistic cascade that significantly reduces the overall amount of uric acid produced in the body. This resulting physiological effect is the sustained lowering of the systemic uric acid concentration, which permits the gradual dissolution of existing solid urate deposits back into the bloodstream for subsequent clearance. The original compound and its own longer-lasting active metabolite, oxypurinol, both contribute to the prolonged inhibition of the XO enzyme, facilitating continuous metabolic regulation.

Advertisements

Dosage and Administration Information

How to Use Uriprim 300: Official Administration Guidelines

Uriprim 300 (Allopurinol) is administered according to a precise protocol focused on controlling daily intake and managing special circumstances.

Administration Scope

Parameter Official Instruction
Route of Administration Primarily Oral via the tablet form (e.g., Uriprim 300 mg). An Intravenous (IV) injection form is also approved for acute, specialized use when oral intake is not tolerated.
Dosing Schedule Initial oral dose is 100 mg once daily. The dose is then titrated in 100 mg increments weekly to a maintenance dose, not to exceed the maximum of 800 mg daily.
Timing in relation to Meals Tablets are typically taken following meals to mitigate the potential for gastrointestinal irritation.
Special Procedural Conditions Adequate daily fluid intake is required to ensure a urinary output of at least 2 liters. Treatment should not be initiated during an acute gout flare.

Procedural Structure and Adjustments

Official administration instructions dictate a gradual approach to therapy. The daily dose may be given as a single unit if it is 300 mg or less. However, oral doses exceeding 300 mg must be administered in divided doses throughout the day.

Dose reduction is a mandatory procedural step for specific populations. The regimen must be substantially reduced in the presence of renal impairment; for example, a dose of 100 mg daily or less may be required for severe impairment. Additionally, if a dose is missed, guidance states that the patient should not double the dose at the next scheduled time.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Primary Efficacy Studies

Studies have investigated whether the drug is associated with a change in the frequency of severe migraine attacks.

The pivotal Phase III trials reported a statistically significant reduction in the mean number of monthly migraine days for participants receiving the drug compared to placebo. These findings were reported in the study authors’ conclusions.


Secondary Endpoints and Attack Characteristics

A secondary analysis of the trial data further examined whether the drug was associated with changes in the severity and duration of attacks.

Research has been conducted to investigate the drug's profile for chronic migraine sufferers and the reported time to onset of potential effect.

Phase IV studies are ongoing and are designed to investigate the long-term profile of the drug. Some research has focused on participants with prior use of older migraine treatments.


Combination Therapy Research

The studies evaluated whether the combination was associated with differences in patient compliance, including comparisons of the observed safety profiles between the combination therapy and monotherapy. Studies also examined the effect of the combined treatment on daily activities and quality of life measures for participants.

Key Studies & References

  1. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
  2. The FDA Approved a New Oral, As-Needed Tablet for Acute Migraine Treatment (Symbravo MOMENTUM, INTERCEPT, MOVEMENT trials)
  3. Migraine Medications - StatPearls (General reference on combination therapy and NSAIDs)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Uriprim 300 (FAQ)

Q: What is the main reason Uriprim 300 is prescribed?

Official regulatory documents indicate that Uriprim 300 is prescribed for two main purposes. One is the management of patients experiencing signs and symptoms of gout. The second is to manage elevated serum and urinary uric acid levels in patients undergoing certain cancer treatment who may experience these high levels as a result of their therapy.

Q: Is Uriprim 300 considered an antibiotic?

No, Uriprim 300 is not classified as an antibiotic. Regulatory information describes it as a xanthine oxidase inhibitor. This means it works by targeting the enzyme responsible for producing uric acid in the body, which is how it helps to manage the condition.

Q: How quickly does Uriprim 300 typically start to work?

The action of reducing uric acid levels in the blood and urine generally begins within two to three days after treatment is started. However, regulatory information notes that the full systemic effect may take a week or more to manifest.

Q: Can Uriprim 300 cause dizziness or tiredness?

Official labeling lists drowsiness and dizziness as possible side effects. Official labeling states that because these effects can occur, caution is indicated when performing tasks like driving or operating machinery.

Q: Are there any common foods or drinks that interact with Uriprim 300?

Generally, there are no known chemical interactions between the medicine and common foods or drinks, according to patient information documents. The medicine is sometimes taken following meals.

Q: What is the list of key ingredients in Uriprim 300 besides the main drug?

The active pharmaceutical ingredient is Allopurinol. Inactive ingredients, also known as excipients, can vary by manufacturer and dose strength, but commonly listed substances include lactose, corn starch, and magnesium stearate.

Q: Can Uriprim 300 affect birth control pills?

Information from health authorities suggests that the medicine does not chemically affect hormonal contraceptives, including birth control pills. However, if the medicine causes vomiting, this may impact the effectiveness of an oral contraceptive pill.

Q: Is it normal to feel a metallic taste after taking Uriprim 300?

A change in taste has been very rarely reported as a side effect in official documentation. It is standard practice to report persistent or bothersome side effects to a healthcare professional.

Q: What is the usual duration of a Uriprim 300 treatment course?

For its primary indication, regulatory information indicates that treatment is often intended for long-term or potentially lifelong use. Treatment is often intended for long-term use, as discontinuing the medicine may result in the return of symptoms.

Q: Are there any known issues with Uriprim 300 and liver function?

Official labeling includes warnings regarding potential liver problems, or hepatotoxicity. Therefore, official documents advise using the medicine with caution in patients who have pre-existing liver disease.

Q: Is Uriprim 300 safe for elderly patients?

Regulatory documents state that no specific information is available regarding the relationship between age and the effects of the medicine in geriatric patients. Dose adjustments are frequently necessary for elderly patients who have reduced kidney function.

Q: Does Uriprim 300 interact with common over-the-counter pain relievers?

The product may be used with certain common pain relievers. Official guidance notes the importance of informing a healthcare provider about all medicines being used, including over-the-counter pain relievers.

Q: What are the most common side effects listed in official documents for Uriprim 300?

Common reported side effects include a skin rash, nausea, vomiting, and drowsiness. Additionally, an increase in joint pain or swelling, sometimes referred to as a gout attack, may occur when first starting the treatment.

Q: Can Uriprim 300 be taken with supplements like vitamins or herbal remedies?

Official guidance notes the importance of informing a healthcare provider about all herbal remedies, vitamins, or supplements being taken. For example, some sources indicate that certain vitamins, like high doses of Vitamin C, may increase the chance of getting kidney stones when taken concurrently.

Q: Is Uriprim 300 suitable for people with a history of kidney stones?

Regulatory documents indicate that patients with a history of kidney stones may be at increased risk for worsening kidney problems while using this medicine. Patients with this history may be at increased risk for worsening kidney problems, according to regulatory documents.

Q: Is Uriprim 300 known to cause sun sensitivity?

Official information includes a recommendation to limit exposure to sunlight and artificial UV rays while using this medicine. This precaution is particularly emphasized during long-term therapy to minimize the risk of non-melanoma skin cancer.

Q: What kind of infections does Uriprim 300 target?

The medicine is prescribed for the management of gout symptoms and for managing high uric acid levels in patients receiving certain cancer therapy. Regulatory information confirms it is not indicated for the treatment of infections.

Q: Is Uriprim 300 considered a broad-spectrum medicine?

No, it is not considered a broad-spectrum medicine. This term is usually applied to antibiotics that treat a wide range of bacterial infections. This medicine is specifically classified as a xanthine oxidase inhibitor, which means it targets the production of uric acid.

Q: Why does the packaging for Uriprim 300 have a special warning about pregnant women?

The regulatory labeling notes that the medicine may harm an unborn baby. It is generally not recommended for use during pregnancy, as there is insufficient evidence available from human studies to confirm its safety for the developing fetus.

Q: Can Uriprim 300 cause changes in sleep patterns?

Official documents list drowsiness as a possible side effect, which may indirectly affect sleep patterns. Official information notes that drowsiness is a possible side effect, which may warrant caution before engaging in activities that require full mental alertness.

Q: Are there any age restrictions for using Uriprim 300?

Regulatory guidelines permit use in children, but generally only for specific, severe conditions, such as high uric acid levels related to cancer therapy. Different administration instructions are used for children compared to adults.

Q: What happens if I stop taking Uriprim 300 before the recommended duration?

The purpose of the medicine is to maintain low uric acid levels, and regulatory information indicates that discontinuing the medicine may cause these levels to slowly return to pre-treatment amounts, typically within seven to ten days, which can result in the return of symptoms.

Q: Does Uriprim 300 have any known drug-drug interactions with blood thinners?

Yes, official documentation mentions a potential interaction with certain blood thinners, such as warfarin. This potential interaction necessitates close monitoring of the blood thinner's effect.

Q: What are the regulatory guidelines regarding the use of Uriprim 300 in children?

Regulatory guidelines permit use in children for specific, severe medical conditions. The administration instructions for children are determined based on their specific needs and condition.

Q: Can Uriprim 300 cause an allergic reaction, and what are the signs?

Yes, serious hypersensitivity reactions, including severe skin rashes such as Stevens-Johnson syndrome, have been reported in official labeling. Official instructions state that if a skin rash or other signs of hypersensitivity (such as fever or flu-like symptoms) develop, the medicine should be stopped and immediate medical attention sought.

Q: Does Uriprim 300 have a risk of C. difficile-associated diarrhea, as mentioned for some other medicines?

Diarrhea is listed as a common side effect in official documents. Specific risks such as C. difficile-associated diarrhea are not universally detailed in general patient information for this product.

Q: What are the contraindications listed for Uriprim 300?

The medicine is formally contraindicated in patients who have a history of a severe reaction to any formulation of allopurinol. Additionally, official documents mention that certain genetic factors, like the presence of the *HLA-B58:01 marker**, may place individuals at a higher risk for severe skin reactions.

Q: What is the active ingredient in Uriprim 300?

The active pharmaceutical ingredient is Allopurinol. This ingredient is then metabolized in the body into its primary active substance, oxipurinol, which provides a longer-lasting therapeutic effect.

Q: Can Uriprim 300 be taken by people with diabetes?

Regulatory documents note that the medicine should be used with caution in patients with pre-existing conditions such as diabetes, as effects may be increased. A healthcare provider will determine the appropriate use based on the patient’s overall condition.

Q: How long does Uriprim 300 stay in the body after the last dose?

The active ingredient, Allopurinol, has a short half-life of about one to two hours in the blood. However, its primary active metabolite, oxipurinol, has a longer half-life, providing sustained action that is mainly eliminated by the kidneys.

Q: What is the guidance on using alcohol while taking Uriprim 300?

Official guidance advises limiting or avoiding alcohol consumption. This is because alcohol may worsen the condition being treated and can also increase the risk of side effects like drowsiness associated with the medicine.

Q: Why is it important to complete the entire course of Uriprim 300, even if I feel better?

The purpose of the medicine is to maintain low uric acid levels, and regulatory information indicates that discontinuing the medicine may cause these levels to slowly return to pre-treatment amounts, resulting in the return of symptoms.

Q: Are there any reported interactions between Uriprim 300 and grapefruit juice?

There are generally no known chemical interactions between the medicine and common foods or drinks, including grapefruit juice, according to official patient information leaflets.

Q: Can Uriprim 300 impact a person's ability to drive or operate machinery?

Yes, because the medicine may cause drowsiness, dizziness, or a decrease in alertness, official labeling states that caution is indicated when performing tasks that require full mental alertness, such as driving or operating machinery.

Q: What are the typical patient profiles who are considered ineligible for Uriprim 300?

Patients who have had a severe allergic reaction to any formulation of allopurinol are considered ineligible. Caution is also advised for those with existing liver or kidney problems and those with certain genetic markers, as detailed in the official prescribing information.

Q: Does taking Uriprim 300 at the same time as other medicines reduce its effect?

Yes, for certain medicines, timing is important. Official instructions require that this medicine be separated by at least three hours when taken with aluminum hydroxide, as taking them together may reduce the effectiveness of Uriprim 300.

Q: Are there specific symptoms that signal a need to stop taking Uriprim 300 immediately?

Yes, official instructions state that if a skin rash or other signs of hypersensitivity (such as fever, flu-like symptoms, or yellowing of the skin or eyes) develop, the medicine should be stopped and immediate medical attention sought.

Q: Why is Uriprim 300 specifically dosed at 300mg?

The 300 mg strength is one of the commonly available tablet forms. Official instructions indicate that this dosage strength is used as a reference point for determining whether a daily dose should be taken as a single unit or divided into multiple doses throughout the day.

Q: How is Uriprim 300 eliminated from the body?

The active ingredient and its long-lasting metabolite are primarily eliminated from the body through the kidneys in the urine. Approximately 20% of the initial active ingredient is also excreted in the feces.

Q: Is Uriprim 300 associated with any psychiatric side effects?

Official documents very rarely list psychiatric effects, but reported side effects include anxiety, agitation, depression, and hostility. It is standard practice to report unexpected changes in mood or behavior to a healthcare professional.

Q: Does Uriprim 300 have a black box warning from the FDA?

Official labeling includes Warnings and Precautions regarding the possibility of severe and sometimes fatal skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These warnings emphasize the need for immediate discontinuation if a rash develops.

Q: Is Uriprim 300 suitable for people with a history of kidney stones?

Regulatory documents indicate that patients with a history of kidney stones may be at increased risk for worsening kidney problems while using this medicine. Patients with this history may be at increased risk for worsening kidney problems, according to regulatory documents.

Q: Are there different forms of Uriprim 300 available (e.g., tablet, capsule)?

The medicine is available as an oral tablet in various strengths, including 300 mg. It is also approved in a separate intravenous (IV) injection powder form for specialized use when oral intake is not possible.

Q: What are the contraindications listed for Uriprim 300?

The medicine is formally contraindicated in patients who have a history of a severe reaction to any formulation of allopurinol. Additionally, official documents mention that certain genetic factors, like the presence of the *HLA-B58:01 marker**, may place individuals at a higher risk for severe skin reactions.

Q: What are the typical patient profiles who are considered ineligible for Uriprim 300?

Patients who have had a severe allergic reaction to any formulation of allopurinol are considered ineligible. Caution is also advised for those with existing liver or kidney problems and those with certain genetic markers, as detailed in the official prescribing information.

Advertisements

How should Uriprim 300 be stored and disposed of?

Storage and Disposal Requirements for Uriprim 300

Uriprim 300 (Allopurinol) must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and kept in its original container, tightly closed, to maintain stability. It is mandatory to keep the tablets out of the sight and reach of children at all times.

Disposal

To discard unused or expired tablets, disposal must align with local regulations. The medication must not be flushed down the toilet, discarded in household trash, or placed into wastewater. Patients are generally instructed to utilize a designated drug take-back program or consult with a local pharmacist for official guidance on proper pharmaceutical disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uriprim 300 found in:

A-Z Index: